Last $148.89 USD
Change Today +3.11 / 2.13%
Volume 591.6K
PRGO On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 2:51 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$146.69
Previous Close
$145.78
Day High
$149.63
Day Low
$146.39
52 Week High
02/28/14 - $168.39
52 Week Low
05/8/14 - $125.37
Market Cap
19.9B
Average Volume 10 Days
867.4K
EPS TTM
$3.86
Shares Outstanding
133.9M
EX-Date
08/27/14
P/E TM
38.6x
Dividend
$0.42
Dividend Yield
0.27%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company’s Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company’s API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

10,220 Employees
Last Reported Date: 10/1/14
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $563.2K
Executive Vice President of Global Operations...
Total Annual Compensation: $470.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $470.3K
Executive Vice President and General Manager ...
Total Annual Compensation: $458.0K
Compensation as of Fiscal Year 2014.

perrigo co plc (PRGO) Key Developments

Perrigo Company Announces Expiration Of Exchange Offer for its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043

Perrigo Company plc announced the expiration of its offer to exchange up to $500,000,000 of its new 1.30% Senior Notes due 2016, $600,000,000 of its new 2.30% Senior Notes due 2018, $800,000,000 of its new 4.00% Senior Notes due 2023 and $400,000,000 of its new 5.30% Senior Notes due 2043, which will be registered under the Securities Act of 1933, as amended, for a like principal amount of its 1.30% Senior Notes due 2016, 2.30% Senior Notes due 2018, 4.00% Senior Notes due 2023 and 5.30% Senior Notes due 2043, pursuant to the terms of a Registration Rights Agreement, dated November 8, 2013, which the company entered into with the initial purchasers of the Outstanding Notes in connection with the Company's offering of the Outstanding Notes. The Exchange Offer expired at 5:00 p.m. Eastern Time, on October 1, 2014. As of that time, approximately $499.98 million of the 2016 Notes, approximately $599.75 million of the 2018 Notes, approximately $800 million of the 2023 Notes and approximately $400 million of the 2043 Notes had tendered in the Exchange Offer. The company will issue certificates for the registered Exchange Notes as soon as practicable.

Perrigo Company to Offer Senior Notes of Various Rates

Perrigo Company announced the extension of its offer to exchange up to $500,000,000 of its new 1.30% Senior Notes due 2016, $600,000,000 of its new 2.30% Senior Notes due 2018, $800,000,000 of its new 4.00% Senior Notes due 2023 and $400,000,000 of its new 5.30% Senior Notes due 2043.

Perrigo Enters into Out-Licensing Agreement of its Preclinical Assets with Imago Pharmaceuticals

Perrigo Company the transfer of its portfolio of preclinical research assets to Imago Pharmaceuticals. Pursuant to the agreement, Perrigo will receive an upfront payment, multiple development-related milestone payments and royalties on any future sales from the portfolio.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $148.88 USD +3.10

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $61.36 USD -0.26
Hospira Inc $49.86 USD -0.21
Mallinckrodt PLC $86.47 USD -0.13
Mead Johnson Nutrition Co $97.05 USD -3.18
Mylan Inc/PA $50.10 USD +0.64
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 82.1x
Price/Sales 4.8x
Price/Book 2.2x
Price/Cash Flow 95.1x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.